Pharma BD Deal Intelligence

BMI Korea Co., Ltd. / Brexogen Inc.

2025 · Licensing/Option · Complete

Brexogen out-licensed BxC-I17e, an exosome-based injectable therapeutic, to BMI Korea under a technology transfer and licensing agreement. Brexogen receives a non-refundable upfront payment of KRW 3 billion (approximately USD 2.3 million as converted in the company release), milestone payments tied to clinical, regulatory and commercial progress, and double-digit percentage royalties on annual net sales, and will share in future licensing revenue if BMI Korea out-licenses to third parties. BMI Korea secured rights to develop BxC-I17e in potential indications excluding immunological indications and will manufacture the product at its own facilities. Total deal value was not disclosed; only the upfront was quantified.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals